Biotech Values

[indiasoutheast]

What implication does the protocal change (reducing the proportion of patients with multi-vessel disease from 50% to 25%) have on its ability to get a multi-vessel label? Specifically, is the ability to get a multi-vessel label significantly reduced?

Any feed-back would be appreciated. Thanks.